Antithrombin supplementation during extracorporeal membrane oxygenation

Study protocol for a pilot randomized clinical trial

Mauro Panigada, Elena Spinelli, Alberto Cucino, Elisa Cipriani, Stefano De Falco, Giovanna Panarello, Giovanna Occhipinti, Antonio Arcadipane, Gabriele Sales, Vito Fanelli, Luca Brazzi, Cristina Novembrino, Dario Consonni, Antonio Pesenti, Giacomo Grasselli

Research output: Contribution to journalArticle

Abstract

Background: Normal levels of plasma antithrombin (AT) activity might decrease heparin requirements to achieve an adequate level of anticoagulation during treatment with extracorporeal membrane oxygenation (ECMO). Acquired AT deficiency during ECMO is common, but formal recommendations on target, timing, and rate of AT supplementation are lacking. Thus, we conceived a pilot trial to evaluate the feasibility and safety of prolonged AT supplementation in patients requiring veno-venous ECMO for respiratory failure. Methods: Grifols Antithrombin Research Awards (GATRA) is a prospective, randomized, single blinded, multicenter, controlled two-arm trial. Patients undergoing veno-venous ECMO will be randomized to either receive AT supplementation to maintain a functional AT level between 80 and 120% (AT supplementation group) or not (control group) for the entire ECMO course. In both study groups, anticoagulation will be provided with unfractionated heparin following a standardized protocol. The primary endpoint will be the dose of heparin required to maintain the ratio of activated partial thromboplastin time between 1.5 and 2. Secondary endpoints will be the adequacy of anticoagulation and the incidence of hemorrhagic and thrombotic complications. Discussion: GATRA is a pilot trial that will test the efficacy of a protocol of AT supplementation in decreasing the heparin dose and improving anticoagulation adequacy during ECMO. If positive, it might provide the basis for a future larger trial aimed at verifying the impact of AT supplementation on a composite outcome endpoint including hemorrhagic events, transfusion requirements, and mortality. Trial registration: ClinicalTrials.gov, NCT03208270. Registered on 5 July 2017.

Original languageEnglish
Article number349
JournalTrials
Volume20
Issue number1
DOIs
Publication statusPublished - Jun 11 2019

Fingerprint

Extracorporeal Membrane Oxygenation
Antithrombins
Randomized Controlled Trials
Heparin
Partial Thromboplastin Time
Research
Respiratory Insufficiency

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology (medical)

Cite this

Antithrombin supplementation during extracorporeal membrane oxygenation : Study protocol for a pilot randomized clinical trial. / Panigada, Mauro; Spinelli, Elena; Cucino, Alberto; Cipriani, Elisa; De Falco, Stefano; Panarello, Giovanna; Occhipinti, Giovanna; Arcadipane, Antonio; Sales, Gabriele; Fanelli, Vito; Brazzi, Luca; Novembrino, Cristina; Consonni, Dario; Pesenti, Antonio; Grasselli, Giacomo.

In: Trials, Vol. 20, No. 1, 349, 11.06.2019.

Research output: Contribution to journalArticle

@article{9be5924909aa4b2e8dadae4e2e3614c9,
title = "Antithrombin supplementation during extracorporeal membrane oxygenation: Study protocol for a pilot randomized clinical trial",
abstract = "Background: Normal levels of plasma antithrombin (AT) activity might decrease heparin requirements to achieve an adequate level of anticoagulation during treatment with extracorporeal membrane oxygenation (ECMO). Acquired AT deficiency during ECMO is common, but formal recommendations on target, timing, and rate of AT supplementation are lacking. Thus, we conceived a pilot trial to evaluate the feasibility and safety of prolonged AT supplementation in patients requiring veno-venous ECMO for respiratory failure. Methods: Grifols Antithrombin Research Awards (GATRA) is a prospective, randomized, single blinded, multicenter, controlled two-arm trial. Patients undergoing veno-venous ECMO will be randomized to either receive AT supplementation to maintain a functional AT level between 80 and 120{\%} (AT supplementation group) or not (control group) for the entire ECMO course. In both study groups, anticoagulation will be provided with unfractionated heparin following a standardized protocol. The primary endpoint will be the dose of heparin required to maintain the ratio of activated partial thromboplastin time between 1.5 and 2. Secondary endpoints will be the adequacy of anticoagulation and the incidence of hemorrhagic and thrombotic complications. Discussion: GATRA is a pilot trial that will test the efficacy of a protocol of AT supplementation in decreasing the heparin dose and improving anticoagulation adequacy during ECMO. If positive, it might provide the basis for a future larger trial aimed at verifying the impact of AT supplementation on a composite outcome endpoint including hemorrhagic events, transfusion requirements, and mortality. Trial registration: ClinicalTrials.gov, NCT03208270. Registered on 5 July 2017.",
author = "Mauro Panigada and Elena Spinelli and Alberto Cucino and Elisa Cipriani and {De Falco}, Stefano and Giovanna Panarello and Giovanna Occhipinti and Antonio Arcadipane and Gabriele Sales and Vito Fanelli and Luca Brazzi and Cristina Novembrino and Dario Consonni and Antonio Pesenti and Giacomo Grasselli",
year = "2019",
month = "6",
day = "11",
doi = "10.1186/s13063-019-3386-4",
language = "English",
volume = "20",
journal = "Trials",
issn = "1745-6215",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Antithrombin supplementation during extracorporeal membrane oxygenation

T2 - Study protocol for a pilot randomized clinical trial

AU - Panigada, Mauro

AU - Spinelli, Elena

AU - Cucino, Alberto

AU - Cipriani, Elisa

AU - De Falco, Stefano

AU - Panarello, Giovanna

AU - Occhipinti, Giovanna

AU - Arcadipane, Antonio

AU - Sales, Gabriele

AU - Fanelli, Vito

AU - Brazzi, Luca

AU - Novembrino, Cristina

AU - Consonni, Dario

AU - Pesenti, Antonio

AU - Grasselli, Giacomo

PY - 2019/6/11

Y1 - 2019/6/11

N2 - Background: Normal levels of plasma antithrombin (AT) activity might decrease heparin requirements to achieve an adequate level of anticoagulation during treatment with extracorporeal membrane oxygenation (ECMO). Acquired AT deficiency during ECMO is common, but formal recommendations on target, timing, and rate of AT supplementation are lacking. Thus, we conceived a pilot trial to evaluate the feasibility and safety of prolonged AT supplementation in patients requiring veno-venous ECMO for respiratory failure. Methods: Grifols Antithrombin Research Awards (GATRA) is a prospective, randomized, single blinded, multicenter, controlled two-arm trial. Patients undergoing veno-venous ECMO will be randomized to either receive AT supplementation to maintain a functional AT level between 80 and 120% (AT supplementation group) or not (control group) for the entire ECMO course. In both study groups, anticoagulation will be provided with unfractionated heparin following a standardized protocol. The primary endpoint will be the dose of heparin required to maintain the ratio of activated partial thromboplastin time between 1.5 and 2. Secondary endpoints will be the adequacy of anticoagulation and the incidence of hemorrhagic and thrombotic complications. Discussion: GATRA is a pilot trial that will test the efficacy of a protocol of AT supplementation in decreasing the heparin dose and improving anticoagulation adequacy during ECMO. If positive, it might provide the basis for a future larger trial aimed at verifying the impact of AT supplementation on a composite outcome endpoint including hemorrhagic events, transfusion requirements, and mortality. Trial registration: ClinicalTrials.gov, NCT03208270. Registered on 5 July 2017.

AB - Background: Normal levels of plasma antithrombin (AT) activity might decrease heparin requirements to achieve an adequate level of anticoagulation during treatment with extracorporeal membrane oxygenation (ECMO). Acquired AT deficiency during ECMO is common, but formal recommendations on target, timing, and rate of AT supplementation are lacking. Thus, we conceived a pilot trial to evaluate the feasibility and safety of prolonged AT supplementation in patients requiring veno-venous ECMO for respiratory failure. Methods: Grifols Antithrombin Research Awards (GATRA) is a prospective, randomized, single blinded, multicenter, controlled two-arm trial. Patients undergoing veno-venous ECMO will be randomized to either receive AT supplementation to maintain a functional AT level between 80 and 120% (AT supplementation group) or not (control group) for the entire ECMO course. In both study groups, anticoagulation will be provided with unfractionated heparin following a standardized protocol. The primary endpoint will be the dose of heparin required to maintain the ratio of activated partial thromboplastin time between 1.5 and 2. Secondary endpoints will be the adequacy of anticoagulation and the incidence of hemorrhagic and thrombotic complications. Discussion: GATRA is a pilot trial that will test the efficacy of a protocol of AT supplementation in decreasing the heparin dose and improving anticoagulation adequacy during ECMO. If positive, it might provide the basis for a future larger trial aimed at verifying the impact of AT supplementation on a composite outcome endpoint including hemorrhagic events, transfusion requirements, and mortality. Trial registration: ClinicalTrials.gov, NCT03208270. Registered on 5 July 2017.

UR - http://www.scopus.com/inward/record.url?scp=85067209378&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067209378&partnerID=8YFLogxK

U2 - 10.1186/s13063-019-3386-4

DO - 10.1186/s13063-019-3386-4

M3 - Article

VL - 20

JO - Trials

JF - Trials

SN - 1745-6215

IS - 1

M1 - 349

ER -